PubMed:32560744 / 630-897 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T2","span":{"begin":230,"end":236},"obj":"CHEBI:36357"},{"id":"T3","span":{"begin":230,"end":236},"obj":"CHEBI:36357"},{"id":"T4","span":{"begin":258,"end":266},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":60,"end":63},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24890"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":60,"end":63},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":258,"end":266},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":30,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":60,"end":63},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T9","span":{"begin":94,"end":99},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T10","span":{"begin":188,"end":196},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":94,"end":99},"obj":"Chemical"},{"id":"T5","span":{"begin":128,"end":130},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":0,"end":267},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":258,"end":266},"obj":"DP"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}

{"project":"yangbin123xm_800_3","denotations":[{"id":"T2","span":{"begin":258,"end":266},"obj":"DP"}],"text":"TRIAL DESIGN: AGILE-ACCORD is a Bayesian multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19."}